TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10598706
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) of the globus pallidus internus (GPi) with L-dopa
Study: 10598706
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) with L-dopa
Study: 1936074
Drug: Moxonidine tablets
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine tablets (treatment A)
Study: 1936074
Drug: Intravenous moxonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxonidine solution (treatment B)
Study: 6152884
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta-receptor blockade
Study: 6152884
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta-receptor blockade
Study: 30887470
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC) chemotherapy
Study: 29506504
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI 28.8 μg
Study: 29506504
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI 14.4 μg
Study: 29506504
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI 7.2 μg
Study: 29695902
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI (all doses)
Study: 25943172
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab 5 mg/mL
Study: 25943172
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab 10 mg/mL
Study: 22344744
Drug: Tandospirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (20 mg)
Study: 22344744
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 mg)
Study: 19865833
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (4 sessions)
Study: 19865833
Drug: Supportive-experiential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-experiential group therapy (4 sessions)
Study: 19865833
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control group, n = 91)
Study: 1850339
Drug: Atropine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (i.v. administration)
Study: 6991446
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg digoxin
Study: 6991446
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg digoxin over four days
Study: 31241381
Drug: Multi-variable analysis
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-variable analysis including doses to the oral cavity, tobacco status, and use of xerogenic medication
Study: 31241381
Drug: Dose-volume histogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-volume histogram (DVH) analysis and principal component analysis (PCA)
Study: 24989855
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg administered intra-operatively, and at 4 and 8 weeks after surgery
Study: 17761570
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation medication use
Study: 15475437
Drug: Budesonide (Pulmicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Pulmicort Turbuhaler) 800 microg twice daily inhalation for 6 months
Study: 15973519
Drug: Gln‐PN (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln‐PN (0.5 g/kg per day; n=15)
Study: 10442372
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen 20 mg/day for 2 years (group A)
Study: 10442372
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT 400 mg/day plus tamoxifen 20 mg/day (group B)
Study: 8755848
Drug: Pheochromocytoma patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pheochromocytoma patients after pharmacological treatment
Study: 8755848
Drug: Pheochromocytoma patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pheochromocytoma patients before any treatment
Study: 1914554
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine delivery system (TTS-1, 0.1 mg/day)
Study: 6351231
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (50 micrograms/puff) one puff per nostril X 4 (daily dose 400 micrograms)
Study: 6351231
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol two puffs per nostril X 2 (daily dose 400 micrograms)
Study: 6351231
Drug: NPEF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPEF and use of antihistamine tablets
Study: 24417602
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition writing about daily activities
Study: 22958476
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) (Flebogamma®, 2 g/kg)
Study: 22958476
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous therapy)
Study: 9682118
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of unpreserved lidocaine (0.5 cc of a 1% unpreserved solution)
Study: 8018617
Drug: Intramyometrial vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramyometrial vasopressin (20 units diluted to 20 ml in normal saline)
Study: 29976228
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment with artemether-lumefantrine (ISTp-AL)
Study: 26221889
Drug: Embolization +
Normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolization + mecobalamin treatment
Study: 26221889
Drug: Embolization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolization treatment
Study: 24215148
Drug: Compassion focused
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compassion focused therapy (CFT) plus treatment as usual (TAU)
Study: 24215148
Drug: Compassion focused
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compassion focused therapy (CFT)
Study: 21136070
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen (30 mg/kg)
Study: 21136070
Drug: Peritonsillar bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar bupivacaine infiltration (1 mg/kg)
Study: 10693094
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg loading dose followed by 5 mg/kg every 12 hours)
Study: 29721510
Drug: Standard pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacotherapy alone (≥21 patients)
Study: 20940522
Drug: Naftopidil 50mg
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50mg once daily (Naf group)
Study: 20940522
Drug: Tamsulosin 0.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2mg once daily (Tam group)
Study: 15823909
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment guided by skin reflectance measurements
Study: 15823909
Drug: Conventional UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional UVB regimen with fixed dosage increments
Study: 11978674
Drug: Sulfonylurea, Metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea, Metformin, or Insulin
Study: 7574132
Drug: Nebulized dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized dexamethasone (1.5 mg/kg)
Study: 2150736
Drug: Aspirin (300-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300-1500 mg daily)
Study: 12324552
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg daily)
Study: 2150736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin with streptokinase
Study: 2150736
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in healthy doctors (primary prevention trials)
Study: 29525822
Drug: Clopidogrel (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300-600 mg loading dose, 75 mg daily thereafter)
Study: 27093052
Drug: Joint reminiscence
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint reminiscence groups (weekly for twelve weeks; monthly maintenance sessions for further seven months)
Study: 24091061
Drug: Mailed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed intervention providing instructions for taste exposure (14 daily tastes of a disliked vegetable with a sticker reward)
Study: 21822913
Drug: Casopitant 90
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 90 mg IV added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Study: 21822913
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Study: 21822913
Drug: Casopitant 90
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 90 mg IV
Study: 18182866
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior program applied twice a week for 50 minutes per session over six weeks
Study: 16235461
Drug: True ES
Normalized name: ALCOHOL 36.58 mL in 59 mL TOPICAL GEL [TRUE ESSENTIALS LEMONGRASS HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: True ES (electrical stimulation) of ST36 and ST38 acupoints with nitroglycerin infusion
Study: 16235461
Drug: Sham ES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ES of ST36 and ST38 acupoints with nitroglycerin infusion
Study: 12198061
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% 8 mL plus 75 microg of clonidine (Group 1)
Study: 12198061
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% 8 mL plus 75 microg of clonidine (Group 3)
Study: 12198061
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% 8 mL plus 0.5 mL of NaCl 0.9% (Group 2)
Study: 10450266
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol before the second speech
Study: 8666102
Drug: Beta 2-agonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonist
Study: 2135708
Drug: Propentofylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline (3 x 300 mg)
Study: 2135708
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x 1 tablet)
Study: 27627654
Drug: AmBisome +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome + SSG (10 mg/kg single dose AmBisome plus 10 days of SSG at 20 mg/kg/day)
Study: 27627654
Drug: AmBisome +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome + Miltefosine (10 mg/kg single dose AmBisome plus 10 days of miltefosine at 2.5 mg/kg/day)
Study: 27627654
Drug: Miltefosine alone
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine alone (2.5 mg/kg/day for 28 days)
Study: 22119570
Drug: Postoperative doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative doxycycline treatment
Study: 10783345
Drug: recombinant follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle stimulating hormone (rFSH; follitropin alpha)
Study: 8938163
Drug: IFN-alpha2a (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a (6 million units starting dose, titrated for 12 months)
Study: 8938163
Drug: IFN-alphaN1 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alphaN1 (6 million units starting dose, titrated for 12 months)
Study: 1612300
Drug: L-hyoscyamine
Normalized name: l-hyoscyamine
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-hyoscyamine
Study: 6428279
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg p.o. q 12 h
Study: 15654172
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg/day and psychotherapy for 8 weeks
Study: 12208593
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg q.d. (n=70)
Study: 12208593
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg b.i.d. (n=71)
Study: 1820897
Drug: Sulphasalazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine treatment
Study: 1901686
Drug: Amoxycillin/clavulanate suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate suspension (Spektramox) for 7 days
Study: 1901686
Drug: Amoxycillin suspension
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin suspension (Imacillin) for 10 days
Study: 31829245
Drug: Topical‐TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical‐TXA
Study: 25041227
Drug: Low-exposure everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n=56)
Study: 22299599
Drug: Ethinylestradiol/levonorgestrel combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol/levonorgestrel combined oral contraceptive (20 µg ethinylestradiol/100 µg levonorgestrel) for 21 days
Study: 10751841
Drug: Topical acne
Normalized name: SalAc 2% Topical Acne Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acne treatments
Study: 7096960
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulfate 2 g/day for 4 weeks
Study: 27038920
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 100 mg every 8 hours for 7 days or until shock reversal
Study: 27038920
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 100 mg in patients with baseline cortisol < 15 ug/dL
Study: 25712437
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical tacrolimus (Tcr)
Study: 17891547
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus music imagery (twice weekly for up to eight sessions)
Study: 16173852
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group therapy (CT)
Study: 16173852
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (including continuation of pharmacotherapy)
Study: 12502654
Drug: Community-based nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based nutrition and exercise intervention (11 weekly nutrition classes, triweekly walking groups)
Study: 15522899
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate 125 mg infused over 1 h
Study: 15522899
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate 250 mg infused over 2 h
Study: 15522899
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) pre-treatment
Study: 2531718
Drug: Placebo pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pre-treatment
Study: 10220271
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ACD-A
Study: 2196353
Drug: Furosemide, 4
Normalized name: Furosemide, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 4 mg/kg in two divided doses on alternate days orally for 8 days
Study: 357451
Drug: Cue-controlled relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-controlled relaxation therapy
Study: 31536511
Drug: Silymarin 700
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 700 mg
Study: 31536511
Drug: Silymarin 420
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 420 mg
Study: 15483018
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy including cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, hormonal synchronization with conjugated estrogens and tamoxifen, followed by definitive radiotherapy or mastectomy and adjuvant chemotherapy.
Study: 15483018
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy for stage IIIA breast cancer patients.
Study: 15483018
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy for stage IIIB non-IBC patients.
Study: 15483018
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy for IBC patients.
Study: 11157314
Drug: Stearic acid
Normalized name: Stearic Acid
DrugBank: Stearic acid (DB03193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stearic acid (1 g fat/kg body wt)
Study: 11157314
Drug: Palmitic acid
Normalized name: Palmitic Acid
DrugBank: Palmitic Acid (DB03796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitic acid (1 g fat/kg body wt)
Study: 11157314
Drug: Unsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsaturated fatty acids (1 g fat/kg body wt)
Study: 9436720
Drug: Dysport (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport (mean dose: 477 units)
Study: 9436720
Drug: Botox (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox (mean dose: 152 units)
Study: 8615058
Drug: 1 alpha,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha, 24 dihydroxyvitamin D3 ointment (4 micrograms/g applied once daily) for 8 weeks
Study: 8615058
Drug: 1 alpha,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha, 24 dihydroxyvitamin D3 ointment and Placebo
Study: 788750
Drug: Prorenoate potassium
Normalized name: Propanoic acid
DrugBank: Propanoic acid (DB03766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prorenoate potassium (40 mg)
Study: 9418687
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg)
Study: 24102851
Drug: Sequential blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential blood pressure measurement
Study: 21211729
Drug: leuproreline 11,25
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuproreline 11,25 mg for 3 years
Study: 21211729
Drug: radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiotherapy plus leuproreline 11,25 mg for 3 years
Study: 19758969
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg)
Study: 2006593
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVB
Study: 2006593
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg TNB
Study: 2006593
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg TNB followed by 1 mg TNB at 60 min
Study: 2006593
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg TNB followed by 0.5 mg TNB at 60 min
Study: 2006593
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg TNB (divided into 2 doses)
Study: 2006593
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of TNB and IVB
Study: 7082535
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg) i.v.
Study: 25810068
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: darbepoetin alfa treatment
Study: 23257490
Drug: Lycopene (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (8 mg Lycored TM per day in two divided doses of 4 mg each)